Policy changes Backwork has recorded, newest first. The most recent change on record is from October 24, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
86,510 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | RTM_Fecal Analysis in the Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | RTM_Evaluation of Dry Eyes | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | RTM_Epithelial Cell Cytology in Breast Cancer Risk Assessment | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | RTM_Pancreatic Enzyme Testing for Acute Pancreatitis | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | RTM_Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | RTM_Beta-Hemolytic Streptococcus Testing | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | RTM_Testing for Alpha-1 Antitrypsin Deficiency | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Rozanolixizumab-noli (e.g., Rystiggo) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Romosozumab-aqqg (e.g., Evenity) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Romidepsin (e.g., Istodax) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Rituximab (e.g., Rituxan) and Biosimilars – Non-Oncologic Indications | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Rituximab (e.g., Rituxan) and Biosimilars and Rituximab/Hyaluronidase (e.g., Rituxan Hycela)- Oncologic Indications | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Risdiplam (e.g., Evrysdi) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Risankizumab (e.g., Skyrizi) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Laparoscopic, Percutaneous, and Transcervical Techniques for Uterine Fibroid Myolysis | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Revakinagene Taroretcel-lwey (e.g., Encelto) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Retifanlimab-dlwr (e.g., Zynyz) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Responsive Neurostimulation for the Treatment of Epilepsy | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Respiratory Syncytial Virus, Immune Prophylaxis with Palivizumab (e.g., Synagis) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Reslizumab (e.g., Cinqair) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Repository Corticotropin Injection | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Renal Artery, Angioplasty/Stenting, Percutaneous | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Remestemcel-L-rknd (e.g., Ryoncil) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Remdesivir (e.g., Veklury) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Reduction Mammoplasty | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Ranibizumab (e.g., Susvimo) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Ramucirumab (e.g., Cyramza) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Radium Ra 223 dichloride for Symptomatic Osseous Metastatic Prostate Cancer (e.g., Xofigo; Ra 223) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Radioimmunotherapy in the Treatment of Non-Hodgkin Lymphoma | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Radiofrequency Ablation of the Renal Sympathetic Nerves as a Treatment for Uncontrolled Hypertension | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Radiofrequency Ablation of Primary or Metastatic Liver Tumors | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Radiofrequency Ablation of Miscellaneous Solid Tumors Excluding Liver Tumors | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Radiofrequency Ablation, Barrett's Esophagus | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Quantitative Sensory Testing | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Quantitative Electroencephalography as a Diagnostic Aid for Attention-Deficit/Hyperactivity Disorder, Cognitive Impairment, or Autism Spectrum Disorder | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Pulsed Pressure, Treatment for Meniere's Disease | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Pulmonary Rehabilitation | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Pulmonary Arterial Hypertension, Infusion and Selected Inhalation therapy | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Proton and Neutron Beam Radiation Therapy | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Proteomics, Screening and Detection of Cancer (e.g., OvaCheck) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Proteomics, Evaluation of Ovarian (Adnexal) Masses (e.g., OVA1, Overa, ROMA) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Proteomics, Predict Response to Chemotherapy (e.g., VeriStrat) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Prostate, Saturation Biopsy | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Prostate Cancer Predicting Risk of Recurrence, Systems Pathology | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Prolotherapy (Sclerotherapy) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Progestin-Releasing Intrauterine Devices (e.g., Kyleena, Mirena, Liletta, Skyla) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Procalcitonin | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Preventive Services | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Preimplantation Genetic Diagnosis, Testing or Treatment | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Prademagene Zamikeracel (e.g., Zevaskyn) | New policy |